MarketBeat
09 May 2026, 08:07 UTC · 20w ago
Verdict
Headline takes no side. We score XERS +0.80 across five claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
RECORLEV revenue nearly doubled to $50 million in Q1, driven by record referrals and new patient starts.
So whatNear-100% growth in the primary revenue driver demonstrates strong commercial traction and directly improves the company's valuation multiples.
More positive than 99% of claims this week
Xeris raised the low end of its full-year revenue guidance to $380 million–$390 million from $375 million–$390 million.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 93% of claims this week
Xeris completed a commercial expansion for RECORLEV, increasing its target healthcare providers from roughly 8,000 to 12,000.
So whatExpanding the sales force and target audience by 50% significantly increases the addressable market and sets the stage for sustained prescription growth.
More positive than 89% of claims this week
Xeris reported Q1 net income of $2.2 million and adjusted EBITDA of $15.1 million, improving by over $11 million and $10.7 million year over year, respectively.
So whatThe swing to GAAP profitability and strong EBITDA margin improvement validates the operating leverage and financial sustainability of the business model.
More positive than 87% of claims this week
GVOKE revenue was flat at $20.8 million, falling slightly below expectations due to Medicare policy changes affecting coverage and costs.
So whatMedicare-related headwinds limiting prescription fills in the Q1 period pose a tangible risk to growth assumptions for a key commercial product.
More negative than 85% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company reported a sharp increase in Q1 revenue, raised its full-year outlook, and saw significant growth for RECORLEV.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+50.0%
Price agrees with the score
$9.79 vs $6.53 close before publication (May 8) · not market-adjusted
XERS chart →